LULU vs MRK: Which Is the Better Buy?
Side-by-side comparison of Lululemon Athletica Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
Lululemon Athletica Inc. · Consumer Cyclical
$128.98
+307.7% upside to fair value
Grade C
VS
Merck & Co., Inc. · Healthcare
$119.07
-4.0% upside to fair value
Grade D
High Quality
QuantHub Verdict
LULU has more upside to fair value
(+307.7%).
LULU trades at a lower forward P/E
(9.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LULU |
MRK |
| Current Price |
$128.98 |
$119.07 |
| Fair Value Estimate |
$525.85 |
$114.30 |
| Upside to Fair Value |
+307.7%
|
-4.0%
|
| Market Cap |
$15.1B |
$294.4B |
| Forward P/E |
9.7x
|
16.2x
|
| EV / EBITDA |
5.6x
|
12.6x
|
| Price / Sales |
1.4x
|
4.5x
|
| Price / FCF |
16.4x
|
23.8x
|
| Revenue Growth YoY |
+0.8%
|
+5.0%
|
| Gross Margin |
56.6%
|
81.5%
|
| Operating Margin |
19.8%
|
41.2%
|
| Return on Equity |
34.8%
|
36.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
6.09%
|
4.2%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Lululemon Athletica Inc. is a premium athletic apparel retailer operating primarily in the consumer cyclical sector with a focus on apparel retail. The company has a strong brand and historically high profitability with a gross margin of 56.6% and ROE of 34.8%, but it faces significant near-term challenges including earnings pressure with a 21.6% decline in earnings in the most recent quarter and…
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, particularly oncology and vaccines. The company benefits from a strong business quality characterized by a durable competitive moat, high gross margins of 81.5%, and a robust return on equity of 36.2%. Despite these strengths, the stock is currently fairly valued but slightly overvalued by 4% relative to its…
Accumulation Zones
| Metric |
LULU |
MRK |
| Zone Low |
$394.39 |
$85.72 |
| Zone High |
$446.97 |
$97.16 |
| In Buy Zone? |
Yes
|
No
|